NUVB Q2 2025 Earnings — Nuvation Bio Inc. Revenue & Financial Results | Market Cap Arena

NUVBNuvation Bio Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+236.8% YoY

Gross Profit

$2M46.7% margin

Operating Income

-$64M-1315.7% margin

Net Income

-$59M-1220.9% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

+56.7%

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$48M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$647M

Total Liabilities

$274M

Stockholders' Equity

$373M

Cash & Equivalents

$248M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$1M	+236.8%
Gross Profit	$2M	$88,000	+2464.8%
Operating Income	-$64M	-$470M	+86.5%
Net Income	-$59M	-$462M	+87.2%

Revenue Segments

License

$4M74%

Product

$1M26%

Geographic Segments

CHINA

$3M70%

UNITED STATES

$1M25%

JAPAN

$241,0005%